secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044533
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal
--------------------------------------------------------------------------------

- Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).
- Cash and equivalents $7.4M at Sep 30, 2024, down from $13.4M at Dec 31, 2023; cash runway into Q1 2025.
- Clinical supply agreement with BeiGene to combine Decoy20 with tislelizumab (anti-PD-1) for advanced solid tumors.
- Phase 1 trial of Decoy20 now allows unrestricted enrollment for weekly dosing at lower dose; well tolerated.
- R&D expenses decreased to $1.5M in Q3 2024 from $2.2M YoY; completed $3M registered direct offering in August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/0001493152-24-044533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer